IMCR News and Press, Immunocore Holdings plc From 07/31/23

2023-07-31 14:43:42 ET Summary Two new Breakout Stocks for Week 31 curated by the MDA model for 10% short-term upside and additional model selections. This week two of four picks gained over 10% in less than a week with peak gains in CLLS +16.8% AUTL+15.5% but the portfolio failed...

2023-07-09 18:15:18 ET Acumen Pharmaceuticals ( NASDAQ: ABOS ), Establishment Labs ( NASDAQ: ESTA ), Arcus Biosciences ( NYSE: RCUS ) and BridgeBio Pharma ( NASDAQ: BBIO ) are four of BTIG's top picks for small and mid-cap healthcare stocks going into the lat...

2023-06-11 03:49:35 ET Summary Immunocore Holdings is a leading biotech firm with a promising pipeline of T cell receptor-based bispecific immunotherapies for cancer, autoimmune diseases, and infectious illnesses. Immunocore's financial growth is driven by strong sales of its flag...

Early on-treatment ctDNA reduction in stable disease patients treated with KIMMTRAK was associated with longer overall survival (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md, 3 June 2023) Immunocore Holdings plc (Nasdaq: IMCR) , a commercial-stage biotechno...

2023-06-01 03:00:29 ET Summary Delcath Systems is close to gaining FDA approval for its HEPZATO KIT, a minimally invasive liver cancer treatment. The company is well-funded and prepared for commercial operations in the U.S. and Europe, with plans to partner with medical centers an...

2023-05-10 08:54:18 ET Immunocore press release ( NASDAQ: IMCR ): Q1 GAAP EPS of -$0.43 misses by $0.05 . Revenue of $55.09M (+86.4% Y/Y) beats by $2.91M . Cash and cash equivalents increased to £337 million ($417 million) as of Mar...

Immunocore Reports First Quarter 202 3 Financial Results and Provides Business Update KIMMTRAK net revenues of £ 42 . 1 million ($ 52. 0 million) in Q 1 202 3 , with continued commercial expansion Ran...

Immunocore to present at the Bank of America Securities 2023 Health C are Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 03 May 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the dev...

2023-04-26 09:00:00 ET Summary Our guest this week is JD Henning, the Founder of Value and Momentum Breakouts and the Momentum Gauges® forecast model. We get the inside scoop of where his models are predicting the market is headed. We dive into how his investing group got...

2023-04-19 04:36:59 ET Swiss biotech company developing novel T-cell receptor-based therapeutics, Engimmune Therapeutics AG ( NASDAQ: IMCR ) appoints Dr. Lars Nieba as CEO. Dr. Søren Mouritsen, co-founder and previous CEO, steps down in a planned transition. ...